I agree the future is bright, but not about the pe

I agree the future is bright, but not about the peer review of ex vivo human blood data delaying the FDA IND. Peer review is common. And it shouldn’t slow up anything in development. Moderna is submitting it’s Phase III data for peer review. But that doesn’t preclude them from announcing a preliminary synopsis of results. The full results are embargoed. However, in an interview Rich Purcell said he’s putting the blood sample results into a patent as well. I think that’s important especially when working with China. So I’d guess they want that awarded before freely revealing sensitive data. But there’s ways for Generex to reveal an overview like all companies do. Jmho.

https://investors.modernatx.com/news-releases...cove-study